Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
2005 1
2006 8
2007 10
2008 10
2009 12
2010 32
2011 46
2012 55
2013 54
2014 53
2015 55
2016 53
2017 51
2018 45
2019 37
2020 38
2021 42
2022 24
2023 22
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

591 results

Results by year

Filters applied: . Clear all
Page 1
Highly sensitive liquid chromatography-mass spectrometry method for the quantitative analysis of mometasone furoate in human plasma: Method validation and application to clinical pharmacokinetic studies.
Heudi O, Jain M, Winter S. Heudi O, et al. Biomed Chromatogr. 2024 Apr 10:e5871. doi: 10.1002/bmc.5871. Online ahead of print. Biomed Chromatogr. 2024. PMID: 38599686
A cycle of three freeze and thaw and stabilities at room temperature and on the autosampler were demonstrated. In addition, MF in the presence of indacaterol and glycopyrronium was proven to be stable at -70C for at least 157 days. The present method was successfully appli …
A cycle of three freeze and thaw and stabilities at room temperature and on the autosampler were demonstrated. In addition, MF in the presen …
The optimal dose of indacaterol for treatment of chronic obstructive pulmonary disease: a systematic review and Bayesian network meta-analysis.
Li X, Zheng J, Luo D, Liu R. Li X, et al. J Thorac Dis. 2024 Jan 30;16(1):344-355. doi: 10.21037/jtd-23-1044. Epub 2024 Jan 9. J Thorac Dis. 2024. PMID: 38410541 Free PMC article.
Indacaterol 75 mug (OR: 0.80; 95% CrI: 0.53-1.21), indacaterol 150 mug (OR: 0.59; 95% CrI: 0.45-0.78), indacaterol 300 mug (OR: 0.35; 95% CrI: 0.26-0.46) were more effective than the placebo in terms of exacerbation rate, and the difference was statistically …
Indacaterol 75 mug (OR: 0.80; 95% CrI: 0.53-1.21), indacaterol 150 mug (OR: 0.59; 95% CrI: 0.45-0.78), indacaterol 300 …
Evaluating β2-agonists as siRNA delivery adjuvants for pulmonary surfactant-coated nanogel inhalation therapy.
Merckx P, Conickx G, Blomme E, Maes T, Bracke KR, Brusselle G, De Smedt SC, Raemdonck K. Merckx P, et al. Eur J Pharm Biopharm. 2024 Apr;197:114223. doi: 10.1016/j.ejpb.2024.114223. Epub 2024 Feb 15. Eur J Pharm Biopharm. 2024. PMID: 38367760
In this work, we assessed a selection of cationic amphiphilic beta(2)-agonists (i.e., salbutamol, formoterol, salmeterol and indacaterol) for their ability to enhance siRNA delivery in a lung epithelial and macrophage cell line. ...As opposed to the least hydrophobic drugs …
In this work, we assessed a selection of cationic amphiphilic beta(2)-agonists (i.e., salbutamol, formoterol, salmeterol and indacaterol …
Digitally monitored inhaled therapy: a 'smart' way to manage severe asthma?
Sykes DL, See YY, Chow ECY, Crooks MG, Cummings H, Robinson M, Watkins K, Thompson J, Overton K, Riches C, Faruqi S. Sykes DL, et al. J Asthma. 2024 Feb 16:1-6. doi: 10.1080/02770903.2024.2316726. Online ahead of print. J Asthma. 2024. PMID: 38323583
METHODS: Consecutive consenting patients meeting criteria for biologics had their existing high-dose ICS/LABA//LAMA combination inhaler/s switched to mometasone/indacaterol/glycopyrronium (114/46/136). Routine clinical data, including blood eosinophils, FeNO, and ACQ-6 sco …
METHODS: Consecutive consenting patients meeting criteria for biologics had their existing high-dose ICS/LABA//LAMA combination inhaler/s sw …
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023.
Matera MG, Calzetta L, Rogliani P, Hanania N, Cazzola M. Matera MG, et al. Lung. 2024 Apr;202(2):119-125. doi: 10.1007/s00408-024-00677-3. Epub 2024 Feb 6. Lung. 2024. PMID: 38321329 Free PMC article.
Compared with tiotropium, other LAMAs were more likely to be associated with reports of CV AEs. Combinations of glycopyrronium with indacaterol or formoterol and umeclidinium with vilanterol significantly reduced reports of CV AEs compared with the respective LAMA. ...
Compared with tiotropium, other LAMAs were more likely to be associated with reports of CV AEs. Combinations of glycopyrronium with indac …
Rapid enantiomeric separation of indacaterol by electrokinetic chromatography.
Salido-Fortuna S, Castro-Puyana M, Marina ML. Salido-Fortuna S, et al. J Chromatogr A. 2024 Feb 22;1717:464696. doi: 10.1016/j.chroma.2024.464696. Epub 2024 Jan 30. J Chromatogr A. 2024. PMID: 38310699 Free article.
The first chiral methodology enabling the separation of indacaterol enantiomers was developed in this work by cyclodextrin-electrokinetic chromatography. Indacaterol (IND) is a chiral drug marketed as a pure enantiomer. Then, the separation and quantification of eac …
The first chiral methodology enabling the separation of indacaterol enantiomers was developed in this work by cyclodextrin-electrokin …
Mixing energy as an adjustment tool for aerodynamic behaviour of an inhaled product: In-vitro and in-vivo effects.
Thalberg K, Matilainen L, Heinonen E, Eriksson P, Husman-Piirainen J, Autio M, Lyberg AM, Göransson S, Kirjavainen M, Lähelmä S. Thalberg K, et al. Int J Pharm. 2024 Feb 15;651:123755. doi: 10.1016/j.ijpharm.2023.123755. Epub 2023 Dec 30. Int J Pharm. 2024. PMID: 38163524 Free article.
This paper describes the development of a fixed dose dry powder combination of indacaterol maleate (Inda) and glycopyrronium bromide (Glyco) in Easyhaler inhaler for a comparative pharmacokinetic (PK) study, as well as the outcome of such a study. ...
This paper describes the development of a fixed dose dry powder combination of indacaterol maleate (Inda) and glycopyrronium bromide …
Indacaterol inhibits collective cell migration and IGDQ-mediated single cell migration in metastatic breast cancer MDA-MB-231 cells.
Ayama-Canden S, Tondo R, Pineros Leyton ML, Ninane N, Demazy C, Dieu M, Fattaccioli A, Sauvage A, Tabarrant T, Lucas S, Bonifazi D, Michiels C. Ayama-Canden S, et al. Cell Commun Signal. 2023 Oct 30;21(1):301. doi: 10.1186/s12964-023-01340-9. Cell Commun Signal. 2023. PMID: 37904233 Free PMC article.
A multiomic analysis was developed that highlighted the splicing factor SRSF6 as a putative master regulator of cell migration and of integrin intracellular trafficking. Indacaterol-induced inhibition of SRSF6 provoked: i) the inhibition of collective and IGDQ-mediated cel …
A multiomic analysis was developed that highlighted the splicing factor SRSF6 as a putative master regulator of cell migration and of integr …
Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo C, Yeap J, Wild R, Compton C, Rothnie KJ, Herth FJF, Quint JK, Ismaila AS. Requena G, et al. Int J Chron Obstruct Pulmon Dis. 2023 Sep 15;18:2039-2054. doi: 10.2147/COPD.S408688. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 37731774 Free PMC article.
This study compared two single-inhaler LAMA/LABA dual therapies, umeclidinium/vilanterol (UMEC/VI) and indacaterol/glycopyrronium (IND/GLY), on moderate-to-severe exacerbation rates in patients with COPD in England. ...
This study compared two single-inhaler LAMA/LABA dual therapies, umeclidinium/vilanterol (UMEC/VI) and indacaterol/glycopyrronium (IN …
Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study.
Sekerel BE, Nell H, Laki I, Pak T, Contreras E, Kolarz A, D'Andrea P, Manga V, Jain M, Vaidya S, Valentin M, Sen B. Sekerel BE, et al. Clin Drug Investig. 2023 Sep;43(9):719-728. doi: 10.1007/s40261-023-01300-8. Epub 2023 Sep 8. Clin Drug Investig. 2023. PMID: 37682405 Free PMC article. Clinical Trial.
BACKGROUND: Indacaterol acetate (IND), a long-acting beta(2)-agonist in combination with mometasone furoate (MF), an inhaled corticosteroid (ICS), is being explored as a once-daily (od) treatment for asthma in children. ...
BACKGROUND: Indacaterol acetate (IND), a long-acting beta(2)-agonist in combination with mometasone furoate (MF), an inhaled corticos …
591 results